

Press release

Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon® 2.0 CE

Liquid biopsy test delivers high sensitivity and specificity and may increase participation in cancer screening programs

Berlin (Germany) and Germantown, MD (U.S.A.), February 14, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that an independent, peer-reviewed article on its blood-based colorectal cancer screening test Epi proColon 2.0 CE was published in the *Journal of Molecular Diagnosis & Therapy*.

According to the study authors Yvette N. Lamb and Sohita Dhillon, Epi proColon® 2.0 CE demonstrated high sensitivity and specificity in case control studies. Furthermore, it provides a patient-friendly option that may increase participation in colorectal cancer screening programs.

“This current comprehensive review adds to the increasing scientific evidence about the clinical performance of our liquid biopsy test Epi proColon”, commented Greg Hamilton, Epigenomics’ Chief Executive Officer. “We are convinced that a convenient, cost-effective blood test like Epi proColon holds significant promise for improving patient adherence to CRC screening, as patients readily accept this method of testing and blood tests could be easily incorporated into routine check-ups.”

The article "Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer" can be accessed on the following website: <http://link.springer.com/article/10.1007/s40291-017-0259-y>

* Sensitivity: the percentage of cancer cases correctly identified; Specificity: the percentage of healthy individuals correctly identified as negative

About Epi proColon

For patients, the test only requires a blood sample drawn as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.

Epi proColon and Epi proColon 2.0 CE are in-vitro PCR (polymerase chain reaction) assays for the qualitative detection of Septin 9 gene methylation in DNA isolated from the patient’s plasma. Cytosine residues of the Septin 9 gene are methylated in colorectal cancer tissue, but not in normal colon mucosa. This tumor-specific methylation pattern can be used to detect cell-free DNA shed into the blood stream by tumor cells. Detection of colorectal cancer-derived DNA in blood plasma using the Septin 9 methylation biomarker was demonstrated in multiple clinical studies, to be a reliable indicator of the presence of colorectal cancer.

For more information, visit www.epiprocolon.com.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' leading products, Epi proColon and Epi proColon 2.0 CE, are blood-based screening tests for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries.

Epigenomics' second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, visit www.epigenomics.com.

Contact Epigenomics AG

Peter Vogt

Vice President Corporate Communication & Investor Relations

Epigenomics AG

Geneststraße 5

10829 Berlin

Phone +49 (0) 30 24345 386

ir@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.